A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease

This study evaluates the efficacy and safety of tetrandrine tablets (60 mg, three times daily) compared to placebo in adult patients with connective tissue disease-related interstitial lung disease. Patients receive standard treatment (glucocorticoids and immunosuppressants) alongside the study drug or placebo for 24 weeks. The study measures changes in lung function, inflammatory markers, lung imaging, quality of life, and safety outcomes.

NCT Number	NCT07319598
Lead Sponsor	Peking University Third Hospital
Conditions	Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
Enrollment	100 participants
Start Date	2023-11-02
Primary Completion	2026-10-15 (estimated)
Study Completion	2027-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-06